White Papers/eBooks

WW for Business: The Real ROI of GLP-1s

Arbital Health
Nov 1, 2023
White Papers/eBooks
 
By: WeightWatchers, Rich Gamret
 
Obesity and related comorbid conditions like type 2 diabetes, cardiovascular disease, and musculoskeletal concerns have been increasing in prevalence and severity in recent years. The costs of treating obesity and its related conditions are also on the rise for employers, driven by medical and pharmacy claims as well as unplanned absences and lost productivity.
New medications — glucagon-like peptide-1s (GLP-1s) — are producing exciting results for patients with obesity, including significant weight loss, improved health outcomes, and improved quality of life. Paired with intensive lifestyle and behavioral programs, GLP-1s are game-changers in the treatment of obesity.
GLP-1 medications drive both costs and savings for individuals and their employers.
While the costs of GLP-1 medications are high, the costs of not addressing weight health
and the conditions associated with excess weight are higher.
 

View More News & Insights from the Arbital Health Team:

Sign-Up for Arbital Health Email Updates

Unlock a wealth of valuable insights and stay ahead of the curve with Arbital Health's exclusive email updates.

Join our community of forward-thinkers and industry leaders to receive the latest news, upcoming webinar alerts, and crucial developments in VBC strategies straight to your inbox. Don't miss out on the opportunity to stay informed, connected, and empowered in the ever-evolving landscape of healthcare.
Arbital_Logo_Full_Color_KO_rgb_022124

98 Battery Street
Suite 400
San Francisco, CA 94111

(415) 226-9393